Mohan Frick Presents ChemoTech at LSI USA '23

Transcription

Mohan Frick  0:04  

I have my medical director on the line in the middle of the night from Bangalore in India. So thank you very much. My name is Mohan. And as I was introduced, I am one of the co founders and CO inventors of the tumor specific electroporation being innovated by Scandinavian ChemoTech, a company based in Sweden, and have been around since 2015. And end of 2016, we made our IPO on NASDAQ in Stockholm, we have today operations in India, and in United States, Middle East, and Sweden. We made us an inventor, what we would call 180 degree in our philosophy of treating cancer. Many other therapies like surgical procedures, radiation, and ablative technologies, focusing on removing or killing cancer cells as quickly as possible. We are chemo tech and we when we develop the tumor specific electroporation, our philosophy is, Why create damage and collateral damage or disturbing the human body's own system. What happens if you can find a balance treatment that works with the body instead, our therapy is built on electrical field that stimulates the cells in cancer tumors to become more vulnerable to low dose of chemotherapy, and to change the character to be more warmer or hot tumors, meaning that they would be more efficient for immunotherapy and immune responses. By working with electricity, the magic of electricity is that it behaves differently in different bodies, different tumors and different locations. And that is the key when it comes to not creating damage. So instead of the older technologies of electroporation that's been static, and focusing on damaging and kill this council cell as quickly as possible ChemoTech, we found out that if we can balance the electrical field, every time is being used to different locations, and different tumors, we create a better treatment option where we spare healthy tissue, and we create a more longer treatment effect and creating apoptosis instead of necrosis. We have today three operations, we have one which is focused on on superficial tumors being launched more in the emerging market. And the same kind of product we have launched here in North America and Europe for taking care of our pets, cats, dogs, and even horses that suffers from cancer. The third one is what I would say one of the most interesting parts of our operation today. And that is to treat deep seated very complex tumors. And for that market, is we focusing on Europe and North America. So why are we here? We're looking to find a way to do this therapy more minimally invasive by a laparoscopic partner or robotic surgical partner. Obviously, we're also here to find some fundings and financial partners to help us to fund our new operations within pancreatic cancer and other deep seated tumors, to a total amount of 6 million US dollars split up in three tranches within the next three years. So by that I hope that this technique is going to be it's going to work so I would like to introduce Dr. Sohail our medical director to share some of the latest knowledge and findings we have done in the pancreatic field and immunological field. So Dr. Sohail now, it's your first slide.

Dr. Sohail Mufti  4:21  

Thank you, Mohan and good afternoon, everybody. This is Dr. Sohail Mufti from Bangalore, India. I'm an on call pathologist by training and trained into transplants on medicine from the University of Edinburg and have been into cancer research for the last two decades with major assignments in oncology projects from a Sanofi and Wattis. I manage the medical affairs of Scandinavian ChemoTech for the operations and research of tumor specific electroporation. Next slide, right number nine more than that again. Thank you. So as Mohan mentioned, tumor specific electroporation, not only does electro chemotherapy on superficial and deep tumors, but it is also an immune therapy. It's it does immuno modulation on the tumor microenvironment with the release of new antigens, tumor specific new antigens and sensitizes. The the the lymphatic system, sensitizing the lymphatic system with the recruitment of CD eight positive T cells, by the sensitization of the dendritic cells which go to the lymph nodes, and CD eight positive cytotoxic T cells are recruited, converting a cold tumor into a hot tumor. It's important to mention here that it does it much better and in a much safer way compared to radiotherapy and never information regarding the effect of radiation on the lymphatic system warrants that a safe and effective new and antigen sensitization of the lymphatic system is important and even the lymph nodes as has been recently published by the University of California on the march 17, that lymph nodes have to be patient and lymph nodes have to be competent to do the immunological sensitization of the microenvironment. Next slide. Yep. That's important for pancreatic cancer treatment, which is a major medical need in oncology at the moment, local regional control or local control of the tumor in advanced and unresectable pancreatic cancer is still a need. And it is important because we know with data that almost 1/3 of the patients still have mortality, because of the local effects of the tumor, local regional recurrence is responsible for patient mortality in the presence of even limited distant metastases, and it has been seen that three year rate death rate from local regional recurrence alone is 23 to 28% Regardless of chemotherapy. So, local treatments are important along with the combinations which may be required for a metastatic cases. So that is why tumor specific electroporation does save electroporation does save electro chemotherapy, along with creates immunological cells that apart from apoptosis of the tumor cells. Next slide. Mohan.

Mohan Frick  7:54  

Yep. And we have one minute, so we have to roll up a little bit quicker.

Dr. Sohail Mufti  8:01  

We have done recently two cases of pancreatic cancer at eurocis, hospital, Ukraine, and these are the pictures from those cases. And you can see on the top right that this is what we are doing with open surgery, providing electroporation on the left you can see there are MRI images, how how the tumor will unresectable. And on the right side, you see the histology images, the right extreme one of the tumor before treatment and the left one after treatment, and you can see the effect of the lighting effect of the therapy on the tumor. Okay. Next slide. These are the immunohistochemistry slides and you can see the recruitment of CD eight positive T cells and CD 45 Positive T cells. So these these images, these immunohistochemistry images show that tumor specific electrode operation converts cold hot tumors and creates an opportunity for immunological cell death and for combinations with immunotherapy next slide.

Mohan Frick  9:28  

All right. So we that was just to give you a little idea of that, how the therapy worked here in Ukraine with the open surgery. So now, just if we can just end Dr. Sohail with the phases in our clinical projects, as we go a little bit over time.

Dr. Sohail Mufti  9:49  

The team at eurocis Hospital Ukraine and I would like to highlight that we are working at combination therapies of tumor specific electroporation with anti PD one and PDL one inhibitors and DSC also has radiosensitizing effect so that we can decrease the radiation dose for various tumors. It's potentially potential better immune modulation compared to radiotherapy with no adverse effect on dendritic cells and T cells. Next slide more. Next. This is the this is the complete project on a tumor specific electroporation for pancreatic cancer. We are working in Ukraine with Genesis hospital, we are taking the trials to Africa to Rwanda and the entire of East Africa, including Kenya, and we are moving to us and to Europe. And we are also taking the pancreatic cancer study to India. As Mohan mentioned, our major endeavor today is to take TSA through the minimally invasive route through the robotic or the laparoscopic routes for multiple applications in pancreatic cancer.

Mohan Frick  10:57  

Thank you so much, Dr. Sohail. With that I would like just to summarize, because I know I'm a little bit over time here. The product is CE marked in Europe. We are not yet started the FDA process here something our strategy, we build our strategy to do that with a partner here in the United States. So that is what we our aims are for this year. And together with building a network of investigators from Europe, down to Africa, as we see here, Scandinavia and here in United States. So with no with that, I would like to thank the audience for listening